Catalent wins ‘Innovation in Process and Formulation Development’ award at CPHI Worldwide for its OptiShell softgel technology

The OptiShell softgel technology uses plant-derived polysaccharides providing scientists with new formulation opportunities.

Softgel capsules have long been recognized by the pharmaceutical community and patients as effective dosage forms for oral drug delivery. Softgels traditionally use gelatin as the film-forming polymer in the capsule shell. The OptiShell softgel technology uses plant-derived polysaccharides providing scientists with new formulation opportunities.

The different physico-chemical and thermo-mechanical properties of OptiShell capsules allow for encapsulation of a wider range of fill formulation types including semi-solids formulated at higher temperatures.

Catalent’s OptiShell technology was one of three finalists selected by a panel of pharma industry experts, and the award was presented at a ceremony on 13 October, at the world’s largest pharmaceutical event, CPHI Worldwide.

“We would like to thank the judging panel for their recognition of our OptiShell softgel platform,” commented Dr Aris Gennadios, Catalent’s President of Softgel Technologies. “OptiShell technology may provide an opportunity for formulators to develop semi-solid, extended release formulations with improved and more consistent therapeutic effectiveness. The “hot-filling” process enables delivery of semi-solid formulations in a patient preferred dose form, while the semi-solid matrix offers extended release profiles that can reduce the maximum API concentration in the bloodstream, decrease the dosing frequency, and, therefore, potentially increase patient adherence.”